Peer-Review Further Supports CLEO’s Ovarian Cancer Detection Technology
Highlights
CLEO’s second peer-reviewed dataset has now been published in medical journal “Diagnostics”
The study concluded that CLEO’s test:
– Correctly identified most cancer cases that were missed by the standard marker CA125;
– Eliminated the majority of "false positive" results caused by CA125 use; and
– Correctly identified the majority of patients with early-stage ovarian cancers.
Peer review validates CLEO’s technology and commercial strategy targeting the surgical triage market where accurate and early cancer identification is critical.
MELBOURNE, AUSTRALIA, 25 March 2024: Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) (CLEO, or the Company) is pleased to announce the publication of further data on its triage test for ovarian cancer.
The article, entitled ‘Reclassification of patients with ambiguous CA125 for optimised pre-surgical triage’ was published in the peer reviewed medical journal, Diagnostics.
A copy of the publication is available here: https://www.mdpi.com/2075-4418/14/7/671
The article concluded:
a) CLEO’s test correctly identified most cancer cases missed by CA125, including a majority of patients with early stage cancers;
b) The test provided superior identification of benign disease to eliminate the majority of "false positive" results obtained using CA125; and
c) The test efficiently discriminated malignant from benign samples.
Commenting on the outcomes published, CLEO Chief Executive, Richard Allman, said:
“These results demonstrate that the CLEO ovarian cancer triage test is far superior to the current standard of care using the CA125 benchmark. Our test will improve the initial clinical investigation process, helping clinicians to triage patients far more effectively than current methods.